Product nameAnti-VEGF Receptor 2 antibody
See all VEGF Receptor 2 primary antibodies
DescriptionGoat polyclonal to VEGF Receptor 2
SpecificityBased on immunoblotting and ELISA, this antibody shows approximately 2% cross-reactivity with recombinant mouse VEGF Receptor 1, and no cross-reactivity with recombinant human VEGF Receptor 1 and VEGF Receptor 3.
Tested applicationsSuitable for: ICC/IF, Indirect ELISA, IHC-P, Flow Cyt, ICC, WB, Neutralising, Blockingmore details
Species reactivityReacts with: Mouse, Rat, Dog
Does not react with: Human
Recombinant fragment from the extracellular domain (Mouse) expressed in mouse NSO cells.
General notesDo not store in frost-free freezer. Endotoxin level is < 10 ng/mg antibody as determined by the LAL (Limulus amebocyte lysate) method.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferPreservative: 0.097% Sodium azide
Constituents: 0.0268% PBS, 0.1% BSA
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab10972 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 5 - 15 µg/ml. (and tissues).|
|Indirect ELISA||Use a concentration of 0.5 - 1 µg/ml.|
|IHC-P||Use at an assay dependent concentration. PubMed: 20882677|
|Flow Cyt||Use a concentration of 3 - 10 µg/ml.
ab37373 - Goat polyclonal IgG, is suitable for use as an isotype control with this antibody.
|ICC||Use at an assay dependent concentration. See Abreview.|
|WB||Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 152 kDa.|
|Neutralising||Use at an assay dependent concentration.|
|Blocking||Use at an assay dependent concentration. PubMed: 20884890|
FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
- Information by UniProt
- CD309 antibody
- CD309 antigen antibody
- EC 188.8.131.52 antibody
Ab10972 positively staining VEGF receptor 2 in paraformaldehyde fixed mouse retinal pigment epithelium (10 µg/ml). Used in conjunction with donkey anti goat IgG (Alexa ® 488) at 1/100.
This image is courtesy of an Abreview submitted on 12th October 2005. We do not have any further information relating to this image.
This product has been referenced in:
- Shen M et al. Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2-mediated STAT3/PI3K/Akt signaling pathway. Int J Mol Med 42:769-778 (2018). Read more (PubMed: 29717775) »
- Wang TC et al. Characterization of highly proliferative secondary tumor clusters along host blood vessels in malignant glioma. Mol Med Rep 12:6435-44 (2015). IHC-Fr ; Rat . Read more (PubMed: 26299849) »